SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer's Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Apr 3

PMID 33805974

Citations 11

Authors

Mercedes Unzeta

Mar Hernandez-Guillamon

Ping Sun

Montse Sole

Affiliations

Soon will be listed here.

Abstract

The semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1) or primary amine oxidase (PrAO), is a deaminating enzyme highly expressed in vessels that generates harmful products as a result of its enzymatic activity. As a multifunctional enzyme, it is also involved in inflammation through its ability to bind and promote the transmigration of circulating leukocytes into inflamed tissues. Inflammation is present in different systemic and cerebral diseases, including stroke and Alzheimer's disease (AD). These pathologies show important affectations on cerebral vessels, together with increased SSAO levels. This review summarizes the main roles of SSAO/VAP-1 in human physiology and pathophysiology and discusses the mechanisms by which it can affect the onset and progression of both stroke and AD. As there is an evident interrelationship between stroke and AD, basically through the vascular system dysfunction, the possibility that SSAO/VAP-1 could be involved in the transition between these two pathologies is suggested. Hence, its inhibition is proposed to be an interesting therapeutical approach to the brain damage induced in these both cerebral pathologies.

Citing Articles

The Dual Role of Amyloid Beta-Peptide in Oxidative Stress and Inflammation: Unveiling Their Connections in Alzheimer's Disease Etiopathology.

Fanlo-Ucar H, Picon-Pages P, Herrera-Fernandez V, Ill-Raga G, Munoz F Antioxidants (Basel). 2024; 13(10).

PMID: 39456461 PMC: 11505517. DOI: 10.3390/antiox13101208.

Vascular-adhesion protein 1 in giant cell arteritis and polymyalgia rheumatica.

Petzinna S, Bauer C, Schafer V Front Med (Lausanne). 2024; 11:1448157.

PMID: 39206172 PMC: 11349539. DOI: 10.3389/fmed.2024.1448157.

Reactive Carbonyl Species Scavenger: Epigallocatechin-3-Gallate.

Luo H, Ou J, Huang J Foods. 2024; 13(7).

PMID: 38611299 PMC: 11012208. DOI: 10.3390/foods13070992.

The Blood-Brain Barrier in Health and Disease.

Al Rihani S, Batarseh Y, Kaddoumi A Int J Mol Sci. 2023; 24(11).

PMID: 37298209 PMC: 10252347. DOI: 10.3390/ijms24119261.

Soluble Vascular Adhesion Protein 1 (sVAP-1) as a biomarker for pregnancy complications: A pilot study.

Danielli M, Thomas R, Gillies C, Lambert D, Khunti K, Tan B PLoS One. 2023; 18(5):e0284412.

PMID: 37253043 PMC: 10228776. DOI: 10.1371/journal.pone.0284412.

References

Nalivaevaa N, Fisk L, Kochkina E, Plesneva S, Zhuravin I, Babusikova E . Effect of hypoxia/ischemia and hypoxic preconditioning/reperfusion on expression of some amyloid-degrading enzymes. Ann N Y Acad Sci. 2005; 1035:21-33. DOI: 10.1196/annals.1332.002. View

Michaud J, Halle M, Lampron A, Theriault P, Prefontaine P, Filali M . Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. Proc Natl Acad Sci U S A. 2013; 110(5):1941-6. PMC: 3562771. DOI: 10.1073/pnas.1215165110. View

Sun P, Esteban G, Inokuchi T, Marco-Contelles J, Weksler B, Romero I . Protective effect of the multitarget compound DPH-4 on human SSAO/VAP-1-expressing hCMEC/D3 cells under oxygen-glucose deprivation conditions: an in vitro experimental model of cerebral ischaemia. Br J Pharmacol. 2015; 172(22):5390-402. PMC: 5341211. DOI: 10.1111/bph.13328. View

Garpenstrand H, Ekblom J, Backlund L, Oreland L, Rosenqvist U . Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in Type 2 diabetes mellitus complicated by retinopathy. Diabet Med. 1999; 16(6):514-21. DOI: 10.1046/j.1464-5491.1999.00103.x. View

Lakhan S, Kirchgessner A, Hofer M . Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med. 2009; 7:97. PMC: 2780998. DOI: 10.1186/1479-5876-7-97. View

Lindsberg P, Carpen O, Paetau A, Karjalainen-Lindsberg M, Kaste M . Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation. 1996; 94(5):939-45. DOI: 10.1161/01.cir.94.5.939. View

Montagne A, Barnes S, Sweeney M, Halliday M, Sagare A, Zhao Z . Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015; 85(2):296-302. PMC: 4350773. DOI: 10.1016/j.neuron.2014.12.032. View

Tanaka S, Tanaka T, Kawakami T, Takano H, Sugahara M, Saito H . Vascular adhesion protein-1 enhances neutrophil infiltration by generation of hydrogen peroxide in renal ischemia/reperfusion injury. Kidney Int. 2017; 92(1):154-164. DOI: 10.1016/j.kint.2017.01.014. View

Smith D, Salmi M, Bono P, Hellman J, Leu T, Jalkanen S . Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. J Exp Med. 1998; 188(1):17-27. PMC: 2525535. DOI: 10.1084/jem.188.1.17. View

10.

Abella A, Garcia-Vicente S, Viguerie N, Ros-Baro A, Camps M, Palacin M . Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner. Diabetologia. 2004; 47(3):429-438. DOI: 10.1007/s00125-004-1346-2. View

11.

Ferrer I, Lizcano J, Hernandez M, Unzeta M . Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer's disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurosci Lett. 2002; 321(1-2):21-4. DOI: 10.1016/s0304-3940(01)02465-x. View

12.

van de Haar H, Burgmans S, Jansen J, van Osch M, van Buchem M, Muller M . Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease. Radiology. 2017; 282(2):615. DOI: 10.1148/radiol.2017164043. View

13.

Hernandez M, Sole M, Boada M, Unzeta M . Soluble semicarbazide sensitive amine oxidase (SSAO) catalysis induces apoptosis in vascular smooth muscle cells. Biochim Biophys Acta. 2006; 1763(2):164-73. DOI: 10.1016/j.bbamcr.2005.11.017. View

14.

Michalicova A, Banks W, Legath J, Kovac A . Tauopathies - Focus on Changes at the Neurovascular Unit. Curr Alzheimer Res. 2017; 14(7):790-801. DOI: 10.2174/1567205014666170203143336. View

15.

Zipfel G, Han H, Ford A, Lee J . Cerebral amyloid angiopathy: progressive disruption of the neurovascular unit. Stroke. 2008; 40(3 Suppl):S16-9. PMC: 2680011. DOI: 10.1161/STROKEAHA.108.533174. View

16.

Ishizaki F . Plasma benzylamine oxidase activity in cerebrovascular disease. Eur Neurol. 1990; 30(2):104-7. DOI: 10.1159/000117321. View

17.

Sinha S, Anderson J, Barbour R, Basi G, Caccavello R, Davis D . Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999; 402(6761):537-40. DOI: 10.1038/990114. View

18.

Hernandez M, Esteban M, Szabo P, Boada M, Unzeta M . Human plasma semicarbazide sensitive amine oxidase (SSAO), beta-amyloid protein and aging. Neurosci Lett. 2005; 384(1-2):183-7. DOI: 10.1016/j.neulet.2005.04.074. View

19.

Lizcano J, Tipton K, Unzeta M . Purification and characterization of membrane-bound semicarbazide-sensitive amine oxidase (SSAO) from bovine lung. Biochem J. 1998; 331 ( Pt 1):69-78. PMC: 1219322. DOI: 10.1042/bj3310069. View

20.

Abbott N, Patabendige A, Dolman D, Yusof S, Begley D . Structure and function of the blood-brain barrier. Neurobiol Dis. 2009; 37(1):13-25. DOI: 10.1016/j.nbd.2009.07.030. View